Stay updated on Grapiprant and Pembrolizumab in NSCLC Clinical Trial
Sign up to get notified when there's something new on the Grapiprant and Pembrolizumab in NSCLC Clinical Trial page.

Latest updates to the Grapiprant and Pembrolizumab in NSCLC Clinical Trial page
- Check4 days agoChange DetectedThe page version was updated from v3.6.2 to v3.6.3. This represents a routine update that does not alter study information or how a user interacts with the page.SummaryDifference0.1%

- Check11 days agoChange DetectedThe page footer now shows Revision: v3.6.2, replacing the previous Revision: v3.6.0; this indicates a new build of the page template rather than substantive changes to the study information.SummaryDifference0.1%

- Check18 days agoNo Change Detected
- Check25 days agoChange DetectedA recruitment status line indicating no participant enrollment was added. Additionally, new help/navigation sections were added (How to Read a Study Record, Common Questions, How to Join a Study), the Interventional label formatting was refined from 'Intervention / Treatment' to 'Intervention/Treatment', and a site revision stamp 'Revision: v3.6.0' was introduced.SummaryDifference0.6%

- Check33 days agoChange DetectedThe page revision was updated from v3.5.4 to v3.5.5. This reflects a metadata version bump for the study page rather than any substantive alteration to the study details.SummaryDifference0.1%

- Check54 days agoChange DetectedThe page's revision tag was updated from v3.5.3 to v3.5.4, representing a platform update. This change reflects an underlying improvement to the site's build rather than the displayed study content.SummaryDifference0.1%

- Check68 days agoChange DetectedThe page now shows Revision: v3.5.3, replacing v3.5.2. This reflects a site-wide version update and does not change the study details or user interactions.SummaryDifference0.1%

Stay in the know with updates to Grapiprant and Pembrolizumab in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Grapiprant and Pembrolizumab in NSCLC Clinical Trial page.